New hope for kids with relapsed cancers: targeted drug trial launches
NCT ID NCT07630974
First seen Jun 06, 2026 · Last updated Jun 18, 2026 · Updated 4 times
Summary
This study tests a new drug called ifinatamab deruxtecan (I-DXd) in children whose solid tumors have come back or did not respond to standard treatment. The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a toxic payload to destroy them. The trial will check how safe the drug is and whether it can shrink tumors in children with specific cancers like neuroblastoma, rhabdomyosarcoma, Wilms tumor, and osteosarcoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILMS TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.